Vertex Pharmaceuticals | VRTX - Interest Expense On Debt

Stock Price
465.76
Daily Change
-6.25 -1.32%
Monthly
3.78%
Yearly
-3.43%
Q1 Forecast
455.43

Vertex Pharmaceuticals reported $3.3M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 685M 9M Sep/2025
Arrowhead Research USD 21.69M 2.69M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
Incyte USD 592K 2K Sep/2025
Insmed USD 20.38M 863K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 327M 22M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 652M 2M Sep/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
United Therapeutics USD 3M 4.3M Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025